LON:RENE ReNeuron Group (RENE) Share Price, News & Analysis → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free RENE Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range 3.38▼ 3.3852-Week Range N/AVolume177,373 shsAverage Volume578,249 shsMarket Capitalization£1.93 millionP/E RatioN/ADividend Yield0.76%Price TargetN/A Stock AnalysisStock AnalysisChartHeadlinesInsider TradesStock AnalysisChartHeadlinesInsider Trades Get ReNeuron Group alerts: Email Address Ad WealthPressIt’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << About ReNeuron Group Stock (LON:RENE)ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.Read More Ad WealthPressIt’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << RENE Stock News HeadlinesApril 27, 2024 | americanbankingnews.comReNeuron Group (LON:RENE) Shares Cross Below Two Hundred Day Moving Average of $4.12April 19, 2024 | americanbankingnews.comReNeuron Group (LON:RENE) Share Price Passes Above 50 Day Moving Average of $3.38April 28, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 17, 2024 | lse.co.ukReNeuron CFO steps down to pursue other opportunitiesApril 2, 2024 | msn.comMedtech firm IQ Endoscopes plans to create 100 new jobs and raise millionsMarch 28, 2024 | lse.co.ukUpland Resources shares soar as company prepares for Sarawak drillingMarch 22, 2024 | msn.comCompany given millions of public money in Welsh Gov's disastrous foray into biotech investments collapses into administrationMarch 20, 2024 | lse.co.ukTRADING UPDATES: ReNeuron appoints administrators as rescue talks failApril 28, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. February 21, 2024 | morningstar.comReNeuron Group PLC RENEFebruary 19, 2024 | lse.co.ukTrident Royalties secures USD40 million revolving credit facilityFebruary 5, 2024 | lse.co.ukTRADING UPDATES: ReNeuron warns; Gama Aviation pledges cash returnFebruary 5, 2024 | msn.comReneuron issues administration warning as biotech firm puts jobs at riskNovember 8, 2023 | lse.co.ukReNeuron interim loss narrows on lower costs; eyes partnershipsSeptember 18, 2023 | finance.yahoo.comReNeuron Group plc (LON:RENE): Is Breakeven Near?May 19, 2023 | finance.yahoo.comReNeuron Group Slides As Insider Purchases Lose Another UK£75kMay 19, 2023 | finance.yahoo.comReNeuron Group Slides As Insider Purchases Lose Another UK£75k \May 16, 2023 | marketwatch.com2023 Neuronal Cell Culture Media Market Size and Research Report in Medical Devices & Consumables Sector | with [104 Pages] and Forecast till 2031May 13, 2023 | marketwatch.comGlobal Retinitis Pigmentosa Treatment & Management Market Report 2023-2030: Top Growth Opportunities and TrendsApril 27, 2023 | marketwatch.comCritical Limb Ischemia Drug Market Size by 2031April 20, 2023 | marketwatch.comPlacental Stem Cell Therapy Market [2023-2030]: Detailed Growth AnalysisApril 7, 2023 | marketwatch.comStem Cell Therapy Market Size, Revenue, and Forecast 2030March 28, 2023 | uk.finance.yahoo.comGlobal Market for Stem Cells 2023: Potential as Disease Treatment Options Fuels Market MomentumMarch 21, 2023 | uk.finance.yahoo.comGlobal Market for Stem CellsMarch 13, 2023 | proactiveinvestors.comReNeuron to present at Advanced Therapies 2023 conferenceFebruary 13, 2023 | proactiveinvestors.comReNeuron Group’s investment potential ‘remains intact’, 2024 cash runway secured, says LiberumJanuary 19, 2023 | marketwatch.comReNeuron Group Cuts 40% of Staff, Cash Extended into 2024See More Headlines Receive RENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ReNeuron Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/20/2020Today4/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:RENE CUSIPN/A CIKN/A Webwww.reneuron.com Phone+44-20-38198400FaxN/AEmployees26Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-5,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-106.77% Return on Assets-37.91% Debt Debt-to-Equity Ratio14.25 Current Ratio1.51 Quick Ratio2.02 Sales & Book Value Annual Sales£783,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.61 Book ValueGBX 4 per share Price / BookN/AMiscellaneous Outstanding Shares57,170,000Free FloatN/AMarket Cap£1.93 million OptionableNot Optionable Beta0.69 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Iain Gladstone Ross B.Sc. (Age 70)BSc (Hons), C.DIR, CH.D, Executive Chairman Comp: $430kMr. John Michael Hawkins A.C.A. (Age 58)Company Secretary, CFO & Director Comp: $192.91kDr. John David Sinden B.A. (Age 73)BA, M.A., MA, Ph.D., Co-Founder Comp: $103kMs. Suzanne HancockChief Operations OfficerDr. Randolph Corteling Ph.D.Chief Scientific OfficerMr. Simon DewChief Business OfficerMore ExecutivesKey CompetitorsPhysiomicsLON:PYCNuformixLON:NFXEvgen PharmaLON:EVGSalvaRx GroupLON:SALVPort Erin Biopharma InvestmentsLON:PEBIView All CompetitorsInsidersJohn HawkinsBought 52,332 shares on 7/12/2023Total: £470,988.00 ($9.00/share)Iain G RossBought 150,000 shares on 6/16/2023Total: £1.20 M ($8.00/share)View All Insider Transactions RENE Stock Analysis - Frequently Asked Questions How were ReNeuron Group's earnings last quarter? ReNeuron Group plc (LON:RENE) issued its earnings results on Monday, July, 20th. The company reported ($35.90) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($50.20) by $14.30. What other stocks do shareholders of ReNeuron Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other ReNeuron Group investors own include 10094 (IRD.TO) (IRD), Sareum (SAR), ValiRx (VAL), IOG (IOG), Dignity (DTY), Tri-Star Resources plc (TSTR.L) (TSTR), Sirius Minerals (SXX), Collagen Solutions plc (COS.L) (COS), RenovaCare (RCAR) and ReNeuron Group (RNUGF). How do I buy shares of ReNeuron Group? Shares of RENE stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:RENE) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ReNeuron Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
